1
|
Qvit N. Microwave-assisted synthesis of cyclic phosphopeptide on solid support. Chem Biol Drug Des 2014; 85:300-5. [PMID: 25042903 DOI: 10.1111/cbdd.12388] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2014] [Revised: 05/03/2014] [Accepted: 06/26/2014] [Indexed: 12/30/2022]
Abstract
Phosphopeptides are important tools for studying intracellular signal transduction events in vitro and in vivo and are also potential drugs due to their direct competition with phosphoprotein recognition elements. Cyclization has been demonstrated to improve peptide selectivity, metabolic stability, and bioavailability. However, cyclic phosphopeptide synthesis may not be straightforward due to the sterically hindered phosphorylated side-chain amino acid derivatives. One option to overcome this hurdle is to use microwave-assisted synthesis, which has been shown to increase efficiency and reduce synthesis time. Herein, a detailed protocol is provided for synthesizing cyclic phosphopeptides using automated microwave. The overall synthesis duration was reduced and yields increased compared with a manual conventional method. This method provides a general, fast and facile way to synthesize cyclic peptides, demonstrating the synthesis of cyclic phosphorylated peptides which are known to be among the most challenging to produce.
Collapse
Affiliation(s)
- Nir Qvit
- Department of Chemical and Systems Biology, School of Medicine, Stanford University, Stanford, CA, 94305-5174, USA
| |
Collapse
|
2
|
Iwata T, Tanaka K, Tahara T, Nozaki S, Onoe H, Watanabe Y, Fukase K. A conformationally fixed analog of the peptide mimic Grb2–SH2 domain: synthesis and evaluation against the A431 cancer cell. MOLECULAR BIOSYSTEMS 2013; 9:1019-25. [DOI: 10.1039/c3mb25462c] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
3
|
Tanaka K, Shirotsuki S, Iwata T, Kageyama C, Tahara T, Nozaki S, Siwu ERO, Tamura S, Douke S, Murakami N, Onoe H, Watanabe Y, Fukase K. Template-assisted and self-activating clicked peptide as a synthetic mimic of the SH2 domain. ACS Chem Biol 2012; 7:637-45. [PMID: 22239652 DOI: 10.1021/cb2003175] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
A new synthetic strategy for obtaining artificial receptors that selectively regulate and/or control specific protein/protein interactions was developed based on the template-assisted and the self-activating click reaction applied to a combinatorial library. Synthetic mimics of the Grb2-SH2 domain, examined as a model case, selectively bound to a target signaling protein to induce cytotoxicity and inhibit tumor growth in vivo.
Collapse
Affiliation(s)
- Katsunori Tanaka
- Department
of Chemistry, Graduate
School of Science, Osaka University, 1-1
Machikaneyama-cho, Toyonaka-shi, Osaka 560-0043, Japan
| | - Sanae Shirotsuki
- Department
of Chemistry, Graduate
School of Science, Osaka University, 1-1
Machikaneyama-cho, Toyonaka-shi, Osaka 560-0043, Japan
| | - Takayuki Iwata
- Department
of Chemistry, Graduate
School of Science, Osaka University, 1-1
Machikaneyama-cho, Toyonaka-shi, Osaka 560-0043, Japan
| | - Chika Kageyama
- Department
of Chemistry, Graduate
School of Science, Osaka University, 1-1
Machikaneyama-cho, Toyonaka-shi, Osaka 560-0043, Japan
| | - Tsuyoshi Tahara
- RIKEN Center for Molecular Imaging Science, 6-7-3 Minatojima-minamimachi,
Chuo-ku, Kobe-shi, Hyogo 650-0047, Japan
| | - Satoshi Nozaki
- RIKEN Center for Molecular Imaging Science, 6-7-3 Minatojima-minamimachi,
Chuo-ku, Kobe-shi, Hyogo 650-0047, Japan
| | - Eric R. O. Siwu
- Department
of Chemistry, Graduate
School of Science, Osaka University, 1-1
Machikaneyama-cho, Toyonaka-shi, Osaka 560-0043, Japan
| | - Satoru Tamura
- Graduate School of Pharmaceutical
Sciences, Osaka University, 1-6 Yamada-oka,
Suita-shi, Osaka 565-0871, Japan
| | - Shunsuke Douke
- Graduate School of Pharmaceutical
Sciences, Osaka University, 1-6 Yamada-oka,
Suita-shi, Osaka 565-0871, Japan
| | - Nobutoshi Murakami
- Graduate School of Pharmaceutical
Sciences, Osaka University, 1-6 Yamada-oka,
Suita-shi, Osaka 565-0871, Japan
| | - Hirotaka Onoe
- RIKEN Center for Molecular Imaging Science, 6-7-3 Minatojima-minamimachi,
Chuo-ku, Kobe-shi, Hyogo 650-0047, Japan
| | - Yasuyoshi Watanabe
- RIKEN Center for Molecular Imaging Science, 6-7-3 Minatojima-minamimachi,
Chuo-ku, Kobe-shi, Hyogo 650-0047, Japan
| | - Koichi Fukase
- Department
of Chemistry, Graduate
School of Science, Osaka University, 1-1
Machikaneyama-cho, Toyonaka-shi, Osaka 560-0043, Japan
| |
Collapse
|
4
|
Iwasaki K, Goto Y, Katoh T, Suga H. Selective thioether macrocyclization of peptides having the N-terminal 2-chloroacetyl group and competing two or three cysteine residues in translation. Org Biomol Chem 2012; 10:5783-6. [PMID: 22419118 DOI: 10.1039/c2ob25306b] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The mode of thioether macrocyclization of peptides containing an N-terminal 2-chloroacetyl group and two or three competing cysteine residues at downstream positions has been extensively studied, leading to a strategy for designated formation of overlapping-bicyclic peptides or dumbbell-type bicyclic peptides.
Collapse
Affiliation(s)
- Kazuhiro Iwasaki
- Department of Chemistry and Biotechnology, Graduate School of Engineering, the University of Tokyo, 7-3-1 Hongo, Tokyo 113-8656, Japan
| | | | | | | |
Collapse
|
5
|
DeLorbe JE, Clements JH, Whiddon BB, Martin SF. Thermodynamic and Structural Effects of Macrocyclization as a Constraining Method in Protein-Ligand Interactions. ACS Med Chem Lett 2010; 1:448-452. [PMID: 21116482 DOI: 10.1021/ml100142y] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The thermodynamic and structural effects of macrocyclization as a tactic for stabilizing the biologically-active conformation of Grb2 SH2 binding peptides were investigated using isothermal titration calorimetry and x-ray crystallography. 23-Membered macrocycles containing the sequence pYVN were slightly more potent than their linear controls; however, preorganization did not necessarily eventuate in a more favorable binding entropy. Structures of complexes of macrocycle 7 and its acyclic control 8 are similar except for differences in relative orientations of corresponding atoms in the linking moieties of 7 and 8. There are no differences in the number of direct or water-mediated protein-ligand contacts that might account for the less favorable binding enthalpy of 7; however, an intramolecular hydrogen bond between the pY and pY+3 residues in 8 that is absent in 7 may be a factor. These studies highlight the difficulties associated with correlating energetics and structure in protein-ligand interactions.
Collapse
Affiliation(s)
- John E. DeLorbe
- Department of Chemistry and Biochemistry, The Institute of Cellular and Molecular Biology, and The Texas Institute of Drug and Diagnostic Development, The University of Texas, Austin, Texas 78712
| | - John H. Clements
- Department of Chemistry and Biochemistry, The Institute of Cellular and Molecular Biology, and The Texas Institute of Drug and Diagnostic Development, The University of Texas, Austin, Texas 78712
| | - Benjamin B. Whiddon
- Department of Chemistry and Biochemistry, The Institute of Cellular and Molecular Biology, and The Texas Institute of Drug and Diagnostic Development, The University of Texas, Austin, Texas 78712
| | - Stephen F. Martin
- Department of Chemistry and Biochemistry, The Institute of Cellular and Molecular Biology, and The Texas Institute of Drug and Diagnostic Development, The University of Texas, Austin, Texas 78712
| |
Collapse
|
6
|
Qvit N, Hatzubai A, Shalev DE, Friedler A, Ben-Neriah Y, Gilon C. Design and synthesis of backbone cyclic phosphorylated peptides: The IkappaB model. Biopolymers 2009; 91:157-68. [PMID: 19025995 DOI: 10.1002/bip.21098] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Phosphopeptides have been used to study phosphorylation and dephosphorylation, which are key events in protein expression. Backbone cyclization has been shown to increase the stability and selectivity of peptides. Backbone cyclic peptides with conformational diversity have produced bioactive peptides with improved pharmaceutical properties, metabolic stability, and enhanced intestinal permeability. We demonstrate a successful methodology for incorporating phospho-amino acids into backbone cyclic peptides. The nuclear factor-kappa B (NF-kappaB) is a latent mammalian protein prototype of dimeric transcription factors that exists in all cell types and plays a pivotal role in a huge number of genes, such as those responsible for chronic and acute inflammatory diseases. To inhibit NF-kappaB, backbone cyclic phosphopeptides were designed and synthesized based on the conserved sequence of the Inhibitor kappa B (IkappaB). The peptides were screened for inhibiting IkappaB ubiquitylation. The best compound showed 90% inhibition at a concentration of 3 microM, and its solution structure showed similarity to a related beta-catenin protein. This general methodology can be use for synthesizing cyclic phosphorylated, as well as backbone cyclic phosphorylated peptides for various biological targets.
Collapse
Affiliation(s)
- Nir Qvit
- Department of Organic Chemistry, Institute of Chemistry, The Hebrew University of Jerusalem, Israel
| | | | | | | | | | | |
Collapse
|
7
|
Jiang S, Liao C, Bindu L, Yin B, Worthy KW, Fisher RJ, Burke TR, Nicklaus MC, Roller PP. Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity. Bioorg Med Chem Lett 2009; 19:2693-8. [PMID: 19362470 DOI: 10.1016/j.bmcl.2009.03.134] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2008] [Revised: 03/06/2009] [Accepted: 03/26/2009] [Indexed: 10/21/2022]
Abstract
Blocking the interaction between phosphotyrosine (pTyr)-containing activated receptors and the Src homology 2 (SH2) domain of the growth factor receptor-bound protein 2 (Grb 2) is considered to be an effective and non-cytotoxic strategy to develop new anti-proliferate agents due to its potential to shut down the Ras activation pathway. In this study, a series of phosphotyrosine containing cyclic pentapeptides were designed and synthesized based upon the phage library derived cyclopeptide, G1TE. A comprehensive SAR study was also carried out to develop potent Grb2-SH2 domain antagonists based upon this novel template. With both the peptidomimetic optimization of the amino acid side-chains and the constraint of the backbone conformation guided by molecular modeling, we developed several potent antagonists with low micromolar range binding affinity, such as cyclic peptide 15 with an K(d)=0.359microM, which is providing a novel template for the development of Grb2-SH2 domain antagonists as potential therapeutics for certain cancers.
Collapse
Affiliation(s)
- Sheng Jiang
- Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, PR China.
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Jiang S, Li P, Peach ML, Bindu L, Worthy KW, Fisher RJ, Burke TR, Nicklaus M, Roller PP. Structure-based design of potent Grb2–SH2 domain antagonists not relying on phosphotyrosine mimics. Biochem Biophys Res Commun 2006; 349:497-503. [PMID: 16945340 DOI: 10.1016/j.bbrc.2006.08.059] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2006] [Accepted: 08/05/2006] [Indexed: 12/01/2022]
Abstract
Development of Grb2-SH2 domain antagonists is considered to be an effective and non-cytotoxic strategy to develop new antiproliferative agents because of their potential to shut down the Ras signaling pathway. We developed a concise route for the efficient synthesis of G1TE analogs on solid phase. Using this route, a series of cyclic peptides that do not rely on phosphotyrosine or its mimics were designed and synthesized based upon the phage library-derived cyclopeptide, G1TE. Considering that Gly7 plays prominent roles for G1TE binding to the Grb2-SH2 domain, we introduced different amino acids in the 7th position. The D-Ala7-containing peptide 3 demonstrates improved binding affinity by adopting favorable conformation for protein binding. This can be rationalized by molecular modeling. The optimization at the Leu2 position was also studied, and the resulting cyclopeptides exhibited remarkably improved binding affinity. Based upon these global modifications, a highly potent peptide ligand 9 was discovered with a Kd = 17 nM, evaluated by Biacore binding assay. This new analog is one of the most potent non-phosphorus-containing Grb2-SH2 antagonists reported to date. This potent peptidomimetic provides a new template for the development of non-pTyr containing Grb2-SH2 domain antagonists and acts as a chemotherapeutic lead for the treatment of erbB2-related cancer.
Collapse
Affiliation(s)
- Sheng Jiang
- Laboratory of Medicinal Chemistry, NCI, NIH, Frederick, MD 21702, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Imhof D, Nothmann D, Zoda MS, Hampel K, Wegert J, Böhmer FD, Reissmann S. Synthesis of linear and cyclic phosphopeptides as ligands for theN-terminal SH2-domain of protein tyrosine phosphatase SHP-1. J Pept Sci 2005; 11:390-400. [PMID: 15635669 DOI: 10.1002/psc.631] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Linear and cyclic phosphopeptides related to the pY2267 binding site of the epithelial receptor tyrosine kinase Ros have been synthesized as ligands for the amino-terminal SH2 (src homology) domain of protein tyrosine phosphatase SHP-1. The synthesis was accomplished by Fmoc-based solid-phase methodology using side-chain unprotected phosphotyrosine for the linear and mono-benzyl protected phosphotyrosine for the cyclic peptides. According to molecular modelling, the incorporation of a glycine residue between Lys (position pY-1 relative to phosphotyrosine) and Asp or Glu (position pY+2) was recommended for the cyclic candidates. The preparation of these peptides was successfully performed by the incorporation of a Fmoc-Xxx(Gly-OAll)-OH (Xxx = Asp, Glu) dipeptide building block that was prepared in solution prior to SPPS. The cyclization was achieved with PyBOP following Alloc/OAll-deprotection. This study demonstrates the usefulness of allyl-type protecting groups for the generation of side-chain cyclized phosphopeptides. Alloc/OAll-deprotection and cyclization are compatible with phosphorylated tyrosine.
Collapse
Affiliation(s)
- Diana Imhof
- Institute of Biochemistry and Biophysics, Biological-Pharmaceutical Faculty, Friedrich-Schiller-University, Philosophenweg 12, D-07743 Jena, Germany.
| | | | | | | | | | | | | |
Collapse
|
10
|
Long YQ, Lung FDT, Roller PP. Global optimization of conformational constraint on non-phosphorylated cyclic peptide antagonists of the Grb2-SH2 domain. Bioorg Med Chem 2003; 11:3929-36. [PMID: 12927853 DOI: 10.1016/s0968-0896(03)00411-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Following our earlier work on a phage library derived non-phosphorylated thioether-cyclized peptide inhibitor of Grb2 SH2 domain, a series of small peptide analogues with various cyclization linkage or various ring size were designed and synthesized and evaluated to investigate the optimal conformational constraint for this novel Grb2-SH2 blocker. Our previous SAR studies have indicated that constrained conformation as well as all amino acids except Leu(2) and Gly(7) in this lead peptide, cyclo(CH(2)CO-Glu(1)-Leu-Tyr-Glu-Asn-Val-Gly-Met-Tyr-Cys(10))-amide (termed G1TE), was necessary for sustenance of the biological activity. In this study, in an effort to derive potent and bioavailable Grb2-SH2 inhibitor with minimal sequence, we undertook a systematic conformational study on this non-phosphorylated cyclic ligand by optimizing the ring linkage, ring configuration and ring size. The polarity and configuration of the cyclization linkage were implicated important in assuming the active conformation. Changing the flexible thioether linkage in G1TE into the relatively rigid sulfoxide linkage secured a 4-fold increase in potency (4, IC(50)=6.5 microM). However, open chain, shortening or expanding the ring size led to a marked loss of inhibitory activity. Significantly, the introduction of omega-amino carboxylic acid linker in place of three C-terminal amino acids in G1TE can remarkably recover the apparently favorable conformation, which is otherwise lost because of the reduced ring size. This modification, combined with favorable substitutions of Gla for Glu(1) and Adi for Glu(4) in the resulting six-residue cyclic peptide, afforded peptide 19, with an almost equal potency (19, IC(50)=23.3 microM) relative to G1TE. Moreover, the lipophilic chain in omega-amino carboxylic acid may confer better cell membrane permeability to 19. These newly developed G1TE analogues with smaller ring size and less peptide character but equal potency can serve as templates to derive potent and specific non-phosphorylated Grb2-SH2 antagonists.
Collapse
Affiliation(s)
- Ya-Qiu Long
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China.
| | | | | |
Collapse
|
11
|
Li P, Zhang M, Peach ML, Zhang X, Liu H, Nicklaus M, Yang D, Roller PP. Structural basis for a non-phosphorus-containing cyclic peptide binding to Grb2-SH2 domain with high affinity. Biochem Biophys Res Commun 2003; 307:1038-44. [PMID: 12878216 DOI: 10.1016/s0006-291x(03)01291-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Blocking the interaction between phosphotyrosine (pTyr)-containing activated receptors and the Src homology 2 (SH2) domain of the growth factor receptor bound protein 2 (Grb2) is considered to be an effective and non-cytotoxic strategy to develop new anti-proliferative agents due to its potential to shut down the Ras activation pathway. Generally, the pTyr-X-Asn minimal binding motif is required for a high-affinity ligand binding to the Grb2-SH2 domain. Using phage-display techniques, we discovered a non-pTyr-containing cyclic peptide G1 with moderate binding affinity from 10(7) different sequences. To understand the structural basis for the high-affinity binding of these novel non-phosphorus-containing inhibitors to the Grb2-SH2 domain, we extensively studied herein the unique functional requirements of the acidic side chain in Tyr-2 position due to the absence of the phosphate group in these non-phosphorylated peptides. A comprehensive SAR study was also carried out to develop potent Grb2-SH2 domain antagonists based upon this novel template. With both the peptidomimetic optimization of the amino acid side-chains and the constraint of the backbone conformation guided by molecular modeling, we developed several potent antagonists with low nanomolar range binding affinity, such as cyclic peptide 20 with an IC(50)=0.026 microM, which is one of the most potent non-phosphorus-containing Grb2-SH2 antagonists reported to date. Whole cell assays indicate that peptide 20 can penetrate the cell membranes and inhibit the association of Grb2 with p185(erbB2) in erbB2-overexpressing MDA-MA-453 cancer cells at low micromolar concentrations.
Collapse
Affiliation(s)
- Peng Li
- Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, 376 Boyles Street, Frederick, MD 21702-1201, USA
| | | | | | | | | | | | | | | |
Collapse
|